Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.

[1]  D. Karnofsky,et al.  Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia , 1967, Cancer.

[2]  J. Pitha,et al.  A clinicopathologic analysis of adriamycin cardiotoxicity , 1973, Cancer.

[3]  S. Garattini,et al.  Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice. , 1978, Cancer treatment reports.

[4]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[5]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[6]  R. Bonow,et al.  Prospective randomized study of the role of N‐acetyl cysteine in reversing doxorubicin‐induced cardiomyopathy , 1982, American journal of clinical oncology.

[7]  J. Doroshow.  Effect of anthracycline antibiotics on oxygen radical formation in rat heart. , 1983, Cancer research.

[8]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[9]  S. Wallace,et al.  Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Wallace,et al.  A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Green,et al.  Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell line. , 1986, Cancer research.

[12]  D. Sullivan,et al.  Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. , 1987, The Journal of biological chemistry.

[13]  J. Wang,et al.  Supercoiling of the DNA template during transcription. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[14]  V. Ferrans,et al.  ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  F. Zunino,et al.  Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. , 1992, Biochimica et biophysica acta.

[16]  E J Orav,et al.  Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. , 1995, The New England journal of medicine.

[17]  G. Link,et al.  Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. , 1996, The Journal of laboratory and clinical medicine.

[18]  S. Swain,et al.  Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Swain,et al.  Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Shinobu Nakamura,et al.  Brain Natriuretic Peptide Is a Predictor of Anthracycline-Induced Cardiotoxicity , 2001, Acta Haematologica.

[21]  A. Gabizon.  Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  J. Schulz-Menger,et al.  Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. , 2001, American heart journal.

[23]  M. Bally,et al.  A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form , 2001, Drug safety.

[24]  S. Lipsitz,et al.  Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Schroeder,et al.  The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925 , 2002, Cancer Chemotherapy and Pharmacology.

[26]  B. Hasinoff,et al.  The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. , 2003, Free radical biology & medicine.

[27]  E. Freireich,et al.  Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. , 2003, Leukemia research.

[28]  S. Swain,et al.  Congestive heart failure in patients treated with doxorubicin , 2003, Cancer.

[29]  Manuela M. Santos,et al.  Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. , 2003, Blood.

[30]  G. Martinelli,et al.  Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy , 2004, Circulation.

[31]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[32]  G. Martinelli,et al.  N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? , 2005, Clinical chemistry.

[33]  M. Pfreundschuh,et al.  NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity , 2005, Circulation.

[34]  Greg Yothers,et al.  Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Giovanni Martinelli,et al.  Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition , 2006, Circulation.

[36]  A. Dogan,et al.  Protective effects of carvedilol against anthracycline-induced cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[37]  L. Constine,et al.  Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Chao-Po Lin,et al.  Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. , 2007, Cancer research.

[39]  E. Winer,et al.  Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Liu,et al.  Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway , 2009, Circulation.

[41]  E. Yeh,et al.  Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. , 2009, Journal of the American College of Cardiology.

[42]  M. Sehested,et al.  Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. , 2009, Toxicology.

[43]  S. Lipsitz,et al.  Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. , 2010, The Lancet. Oncology.

[44]  F. Veglia,et al.  Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. , 2010, Journal of the American College of Cardiology.

[45]  C. Zechner,et al.  Uncoupling protein downregulation in doxorubicin-induced heart failure improves mitochondrial coupling but increases reactive oxygen species generation , 2011, Cancer Chemotherapy and Pharmacology.

[46]  S. Hunger,et al.  Long-term Results Of the Pediatric Oncology Group Studies For Childhood Acute Lymphoblastic Leukemia 1984-2001: A Report From The Children’s Oncology Group , 2009, Leukemia.

[47]  S. Zimeras,et al.  Cardioprotective effect of metoprolol and enalapril in doxorubicin‐treated lymphoma patients: A prospective, parallel‐group, randomized, controlled study with 36‐month follow‐up , 2010, American journal of hematology.

[48]  W. Oyen,et al.  Scintigraphic Techniques for Early Detection of Cancer Treatment–Induced Cardiotoxicity , 2011, The Journal of Nuclear Medicine.

[49]  D. Neuberg,et al.  The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. , 2011, European journal of cancer.

[50]  Randolph P. Martin,et al.  Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. , 2011, The American journal of cardiology.

[51]  E. Yeh,et al.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity , 2012, Nature Medicine.

[52]  A. Goldhirsch,et al.  Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  Juerg Schwitter,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[54]  M. Anscher,et al.  Abstract LB-339: Cause of death in cancer survivors , 2012 .

[55]  S. Lipsitz,et al.  Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes , 2012, Pediatrics.

[56]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[57]  M. Bansal.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. The OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of , 2013 .

[58]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[59]  J. Esteve,et al.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of , 2013, Journal of the American College of Cardiology.

[60]  G. Armstrong,et al.  Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  J. Esteve,et al.  Reply: Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. , 2013, Journal of the American College of Cardiology.

[62]  S. Lipsitz,et al.  Impact of hemochromatosis gene mutations on cardiac status in doxorubicin‐treated survivors of childhood high‐risk leukemia , 2013, Cancer.

[63]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[64]  Y. Lam,et al.  Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. , 2013, International journal of cardiology.

[65]  P. Vejpongsa,et al.  Topoisomerase 2β: A Promising Molecular Target for Primary Prevention of Anthracycline‐Induced Cardiotoxicity , 2013, Clinical pharmacology and therapeutics.